Eucomed challenges "irrational" national decisions:
This article was originally published in Clinica
Six issues that have been identified as priorities by the Eucomed Legal Issues Group for 2005 include challenging irrational national reimbursement decisions as well as continuing scrutiny and understanding of national procurement practices. These reflect the mounting obstacles that industry still faces despite regulatory convergence. The other four issues are: late payments and what can be learnt from the Spanish and Italian approaches; new technologies - the need for appropriate regulatory mechanisms to avoid the inevitable drift towards inappropriate and expensive pharma-based systems; strategic future of regulation - reform of the Medical Devices Directive and related legislation; and analysis of the implications of EU horizontal measures.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.